登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002907证券简称：华森制药公告编号：2025-090 重庆华森制药股份有限公司 关于公司特殊医学用途配方食品生产许可证变更的公告 特殊医学用途配方食品是为了满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或 膳食的特殊需要，专门加工配制而成的配方食品。该类产品必须在医生或临床营养师指导下，单独食用 或与其他食品配合食用。 公司甘亦美?流质配方食品是一款专为10岁以上需严格限制脂肪、消化吸收障碍等患者研发的特医食 品。其采用0脂肪、0纤维、主以碳水、辅以短肽的科学配方，碳水化合物供能比高达87%，能快速供能 且无消化负担，易于吸收。同时添加核心维生素与矿物质，保障营养均衡、电解质平衡。适用于急性胰 腺炎、短肠综合征、胃肠功能损伤等疾病状态的营养支持，亦可作为结肠镜检查前标准化的清肠流质饮 食，以提高肠道准备质量。 据Grand View Research数据显示，2024年，全球特殊医学用途配方食品（FSMP）市场规模估计为248亿 美元，预计到2030年，将以5.13%的年复合增长率增长至334.9亿美元。2024年，中国特殊医学用 ...

据Grand View Research数据，2024年全球特医食品市场规模达248亿美元，预计2030年将以5.13%的年复 合增长率增至334.9亿美元；中国市场表现更为突出，2024年规模约164亿元人民币，占全球9.15%的市 场份额，预计2030年将以6.58%的年复合增长率攀升至240亿元人民币。目前我国特医食品临床使用率 远低于发达国家水平，随着居民健康意识提升、临床营养支持需求增加，行业发展空间广阔。 中证报中证网讯（王珞）2025年12月30日，重庆华森制药股份有限公司（002907.SZ，下称"华森制 药"）披露公告称，公司已收到重庆市市场监督管理局核准签发的《特殊医学用途配方食品生产许可 证》（许可证编号：SC12850000050231）。 公告显示，公司于2025年11月18日提交相关食品生产许可申请，经监管部门审查符合法定条件，最终获 得行政许可批复。此次许可证变更的核心亮点的是新增特殊医学用途配方食品生产类别，为公司已获批 注册的"甘亦美®"流质配方食品落地生产提供关键支撑。该产品专为10岁以上需严格限制脂肪、存在消 化吸收障碍等人群研发，采用0脂肪、0纤维的科学配方，以碳水化合 ...

Healthcare Policy - National Healthcare Security Administration held a series of discussions on the adjustment of the disease-based payment grouping scheme 3.0, involving over 70 representatives from medical institutions and industry associations [1] Drug and Medical Device Approvals - Shijiazhuang Pharmaceutical Group's application for the listing of Pertuzumab injection has been accepted by the National Medical Products Administration, targeting HER2-positive breast cancer [1] - Huason Pharmaceutical received a registration certificate for its special medical purpose formula food, Ganyimei®, designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders [2] - United Imaging Healthcare's subsidiary obtained a medical device registration certificate for its color Doppler ultrasound diagnostic system, enhancing its product range across various market segments [3] - Yiling Pharmaceutical's application for the listing of Memantine Hydrochloride, a drug for treating moderate to severe Alzheimer's disease, has been approved [4] - Zhifei Biological's clinical trial application for a freeze-dried varicella inactivated vaccine has been accepted by the National Medical Products Administration [10] - Changchun High-tech's subsidiary received approval for a clinical trial of an acellular pertussis-diphtheria-tetanus combined vaccine for adolescents and adults [11] Capital Market Activities - Peking University Pharmaceutical announced the release of 34,615,386 shares from pledge, representing 51.52% of the pledged shares and 5.81% of the total share capital [5] - Kelun Pharmaceutical received approval for a registration of 4 billion yuan in ultra-short-term financing bonds, with a validity period of 2 years [6][7] - Baili Tianheng decided to delay its global offering and listing of H-shares due to current market conditions [8] - Aipeng Medical announced a plan for a shareholder to reduce holdings by up to 1% of total shares, citing personal funding needs [12] - Hendi Pharmaceutical's shareholders plan to collectively reduce their holdings by up to 2.33% of total shares for personal financial planning [13] Financial Adjustments - Baihua Pharmaceutical plans to use 1.91 billion yuan from its capital reserve to cover losses, primarily due to goodwill impairment from a previous major asset restructuring [14]